US IPO hopefuls forge ahead with listing plans amid market swings

Multiple companies, including Yesway, Alamar Biosciences, Kailera Therapeutics, National Healthcare Properties, and Pershing Square, launched or advanced IPO roadshows as issuers test appetite amid Middle East conflict and reduced volatility. The article notes the VIX fell below 20 last week for the first time in over a month, suggesting improving market stability, though uncertainty remains after U.S.-Iran talks failed to produce a deal. The main takeaway is a cautiously constructive setup for the IPO market, with activity likely to pick up if volatility stays contained.

Analysis

The interesting trade here is not the headlines around volatility, but the disconnect between macro uncertainty and capital-markets supply. A rising IPO pipeline during a geopolitical shock usually means sponsors believe the market is closer to a tradable clearing level than a true risk-off regime; that tends to favor higher-quality, smaller issuers that can be priced with discipline, while punishing late-cycle, story-driven deals that need multiple expansion to work.

For listed proxies, the clean beneficiary is the fee stream attached to execution and secondary activity rather than the IPO names themselves. If the window stays open for 6-10 weeks, expect a modest lift in exchange and market-structure names, but the bigger second-order winner is in pre-IPO funding markets: venture-backed healthcare and biotech issuers will likely accelerate filings to beat any renewed volatility, which could pressure pricing terms and reduce upside for new investors while improving the probability of deal completion.

The contrarian view is that the market may be underestimating how fragile this reopening is. IPO pipelines can look robust right before a volatility spike, and with geopolitical risk unresolved, a single escalation can shut the window fast; in that case, the most levered losers are recent roadshow launches and pre-revenue healthcare names that depend on a clean bookbuild. NHPBP stands out as a small, direct expression of this theme: if the window remains open, the issue can clear, but downside is asymmetric if risk appetite rolls over before pricing.

Key Decisions for Investors

• Buy a short-dated call spread on IPO/market-structure exposure via IPO ETF (IPO) for the next 4-8 weeks; upside is tied to a reopening, while premium risk is capped if the window closes again.
• Initiate a cautious long in NHPBP only into confirmed pricing, not the roadshow; if priced attractively, the setup is a first-week pop trade, but if volatility reaccelerates the deal can be repriced or delayed.
• Short a basket of recent pre-revenue biotech IPO candidates against a long in profitable healthcare services names over 1-3 months; the market will reward certainty over pipeline stories if volatility returns.
• Pair long low-beta, cash-generative healthcare/real-estate issuers with short high-duration IPOs to express the risk-appetite bifurcation; target 5-8% relative outperformance if the IPO window remains open but choppy.
• For event-driven desks, keep dry powder for secondary breakdowns in names that launch roadshows now; a failed bookbuild often creates a 10-20% entry discount within days, especially if the geopolitical tape worsens.